Journal Information
Vol. 37. Issue 12.
Pages 981-986 (December 2018)
Download PDF
More article options
Vol. 37. Issue 12.
Pages 981-986 (December 2018)
Original Article
DOI: 10.1016/j.repce.2018.02.022
Open Access
Cardiac papillary fibroelastoma: Report of a surgical series
Fibroelastoma papilar cardíaco: relato de uma série cirúrgica
Joana Duarte Rodriguesa,
Corresponding author

Corresponding author.
, João Ferreirab, Jorge Almeidab, Manuel Campeloa, Maria Júlia Maciela, Paulo Pinhob
a Department of Cardiology, Centro Hospitalar de São João, Porto, Portugal
b Cardiothoracic Surgery Department, Centro Hospitalar de São João, Porto, Portugal
Related content
Rev Port Cardiol. 2018;37:987-910.1016/j.repce.2018.12.009
Miguel Sousa-Uva, Nuno Cardim
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (2)
Table 1. Baseline clinical characteristics of the study population (n=26).
Table 2. Echocardiographic features of the study population (n=26).
Show moreShow less

Papillary fibroelastoma (PFE) is a rare primary benign tumor of cardiac origin that predominantly affects the cardiac valves. Although most patients are asymptomatic, serious complications may result given their propensity for embolization. Advances in imaging technology have enabled earlier detection and more accurate characterization of these tumors. We report a case series, describing clinical presentation, treatment and outcome.


Institutional records of a tertiary center between 1997 and 2015 were reviewed for all patients diagnosed with PFE treated surgically and confirmed histologically. Demographic and clinical characteristics, echocardiography findings and treatment modalities were analyzed and recurrence at follow-up was studied.


A total of 26 patients (69% male), aged 54±18 years, had a PFE. Clinically, PFE presented with neurologic deficits in eight cases and was asymptomatic in 65.4%. The mitral valve surface was the predominant tumor location (53.8%), followed by the aortic valve (34.6%). Tumor size ranged between 3 mm and 22 mm, 26.9% had a pedicle and 42.4% were mobile. All patients were treated successfully by complete resection, isolated in 88.5% and with valve repair in three cases. No other cardiac procedure was performed concomitantly and there were no major postoperative complications. Median follow-up was 61±49 months and no tumor recurrence or embolic events were documented.


Fibroelastomas are generally small, single and detected by chance during routine imaging exams. Complete surgical resection of the tumor has an excellent prognosis and appears to be a good strategy.

Cardiac tumor
Cardiovascular event

Os fibroelastomas papilares (FP) são tumores benignos primários de origem cardíaca, que afetam predominantemente as válvulas. Embora a maioria dos doentes seja assintomática, podem ocorrer complicações graves por causa de sua propensão para embolizar. A melhoria das técnicas de imagem moderna permitiu a deteção precoce e melhor caracterização desses tumores. É nosso objetivo apresentar a casuística do Serviço, descrever a apresentação clínica, o tratamento e os resultados cirúrgicos.


Foram revistos os dados institucionais entre 1997 e 2015, de todos os doentes com o diagnóstico de FP tratados cirurgicamente, com confirmação histológica. Foram analisadas as características demográficas, clínicas, ecocardiográficas e cirúrgicas. A recorrência durante o seguimento foi também objeto do estudo.


Foram identificados 26 doentes (69% homens), de 54±18 anos, com FP. O FP apresentou-se com deficit neurológico em oito doentes, nos restantes casos o diagnóstico foi casual. A superfície valvular mitral foi a localização mais frequente (53,8%), seguida da válvula aórtica (34,6%). A dimensão do tumor variou de 3 a 22 mm, 26,9% eram pediculados e a mobilidade estava presente em 42,4% dos casos. Todos os doentes foram tratados com resseção completa, isolada em 88,5% e com reparação valvular em três casos. Nenhum outro procedimento cardíaco foi feito concomitantemente e não se registaram complicações cardíacas major no pós-operatório. O período mediano de seguimento foi de 61±49 meses, não foi documentada recorrência do tumor nem de eventos embólicos.


Os fibroelastomas são geralmente pequenos, isolados e mais frequentemente detetados incidentalmente em exames de rotina. A recessão cirúrgica completa do tumor tem um excelente prognóstico e parece ser uma boa estratégia.

Tumor cardíaco
Evento cardiovascular
Full Text

Papillary fibroelastoma (PFE) is a rare primary benign tumor of cardiac origin, accounting for approximately 10% of all cardiac tumors.1 They can occur anywhere on the endocardium, but are more common in the left heart and display a predilection for valve structures, the aortic valve being most commonly affected.2 Although most patients are asymptomatic, serious complications may occur such as acute valve dysfunction or embolization, giving rise to a wide variety of presenting features including neurologic events, acute coronary syndrome and distal embolic events.3–5

Thanks to improved echocardiographic resolution and modern imaging modalities, these tumors are increasingly often recognized. It is therefore possible that the real incidence of PFE is underestimated.6 Clinicians must be able to decide how to manage patients with incidental echocardiographic findings as well as those with symptoms that may be attributed to these masses. Few systematic reviews or comprehensive studies have provided results that validate either a medical or a surgical approach, although in an recent single-center retrospective study, Tamin et al. concluded that patients with echocardiographically suspected PFE who do not undergo surgical removal have higher rates of cerebrovascular accident and mortality.7 Given that there have been no randomized clinical trials aimed at defining the optimal treatment strategy, we decided to review our institution's surgical experience with PFE over an 18-year period. We present our findings and discuss demographic, clinical and echocardiographic characteristics and current treatment approaches along with results of our follow-up assessments.


We performed a retrospective review of all patients diagnosed with cardiac PFE who underwent surgical excision at our institution between January 1997 and December 2015. Patients were identified from the cardiovascular surgery and pathology databases. Cardiac PFE was the primary indication for surgery, and therefore patients undergoing heart surgery for other reasons in which the tumor was a additional finding were excluded from our study. Clinical histories, echocardiographic reports, operative notes and histopathologic findings were reviewed. Demographic characteristics including age and gender, clinical data including presenting symptoms, concurrent cardiac disease, comorbidities, tumor location and left ventricular ejection fraction, operative procedures, and follow-up findings were collected. Since all patients with PFE diagnosed pathologically from surgical specimens had at least one transthoracic echocardiography (TTE) and/or transesophageal echocardiography (TEE) leading to the diagnosis, the echocardiographic characteristics of the tumor including location, number, attachment characteristics, movement, size and valvular involvement were also collected. A presumed diagnosis of cardiac PFE by echocardiography was based on its appearance, which is usually of a small, mobile, pedunculated or sessile valvular or endocardial mass that frequently flutters or prolapses into the cardiac chambers during systole or diastole. They may appear speckled with echolucencies and a stippled pattern near the edges, which correlates with the papillary projections on the surface of the mass.8,9

Neurologic events were attributed to the PFE in patients with no concurrent atrial fibrillation and no significant carotid or cardiac disease. Follow-up data were collected from telephone interviews of patients. The endpoints were clinical embolic events, need for further cardiac surgery due to tumor recurrence, or death at follow-up.

Results are expressed as mean ± standard deviation for continuous variables. Selected variables were compared between groups by the Student's t test for unpaired data when a normal distribution was demonstrated; otherwise, the nonparametric Mann-Whitney U test was used. Categorical variables are summarized as count and percentages and compared between groups using the Pearson chi-square or Fisher's exact test, as appropriate. Statistical significance was set at p<0.05. Data were analyzed using IBM SPSS Statistics for Windows, version 21 (IBM Corp., Armonk, NY, USA).


A total of 26 patients, 18 male (69.2%), mean age 54.3±18.4 years (range 24-88 years), underwent surgical excision of one or more cardiac PFE between 1997 (first record of PFE in our database) and 2015 (Table 1). Over the years, increasingly frequent identification of PFE was observed (Figure 1), with the largest number of cases diagnosed in 2012 (n=6). None of the patients had undergone previous cardiac surgery and the most common cardiac comorbidities were hypertension, hyperlipidemia and diabetes.

Table 1.

Baseline clinical characteristics of the study population (n=26).

Age in years, mean ± SD  54.3±18.4 
25-40, n (%)  9 (34.6) 
41-60, n (%)  6 (23.1) 
61-80, n (%)  10 (38.5) 
81-90, n (%)  1 (3.8) 
Caucasian, n (%)  26 (100) 
Previous cardiac surgery, n (%)  0 (0) 
Cardiac comorbidities
Hypertension, n (%)  8 (30.8) 
Hyperlipidemia, n (%)  5 (7.7) 
Diabetes, n (%)  2 (7.7) 
Smoking, n (%)  7 (26.9) 
Heart failure, n (%)  0 (0) 
Heart rhythm
Sinus rhythm, n (%)  25 (96.2) 
Atrial fibrillation, n (%)  1 (3.8) 
Clinical presentation
Neurologic deficits, n (%)  8 (30.8) 
Asymptomatic, n (%)  17 (65.4) 
Other, n (%)  1 (3.8) 
Figure 1.

Increased diagnosis of PF over the years with a peak of cases in 2012 (n=6).


All tumors from the 26 patients included in this report were confirmed histopathologically as PFE following complete excision. In 26 patients, there were 28 lesions; 24 patients had solitary tumors located on valves (Table 2). Tumor size varied from 3 mm to 22 mm (mean 9.9±3.7), 26.9% had a pedicle and 42.37% were mobile. The valve surface was the predominant location, comprising 92.3% of the total, with 53.8% on the mitral valve, followed by the aortic valve in 34.6%, left ventricular wall in 3.8% and right atrium in 3.8%. In one case (3.8%) the aortic valve and left ventricle were simultaneously involved. The majority of tumors arose in the left heart (96.2%). Clinically, PFE presented with neurologic deficits in eight cases (in which echocardiography was performed to exclude a cardiac embolic source), 65.4% were asymptomatic and were identified by routine echocardiography, and in one patient it presented as shortness of breath not directly related to the presence of a cardiac mass. The tumor was thus an incidental finding in most patients.

Table 2.

Echocardiographic features of the study population (n=26).

  Study population, n (%) 
Reason for TTE
Routine  17 (65.4) 
Exclude cardiac source of embolism  8 (30.8) 
Other  1 (3.8) 
Location of lesion
Aortic valve  9 (34.6) 
Mitral valve  14 (53.8) 
Right atrium  1 (3.8) 
Left ventricle  1 (3.8) 
Aortic valve and ventricular myocardium  1 (3.8) 
Number of lesions/patient
24 (92.3) 
2 (7.7) 
<5 mm  1 (3.8) 
5-10 mm  17 (65.4) 
11-15 mm  6 (23.1) 
>15 mm  2 (7.7) 
Pedicle  7 (26.9) 
None  15 (57.7) 
Low  6 (23.1) 
High  5 (19.2) 
LVEF >55%  26 (100) 

LVEF: left ventricular ejection fraction; TTE: transthoracic echocardiography.

Stroke was the clinical presentation in 30.8% of cases; these patients were younger, aged 42±17 years (p=0.026). Patients with neurologic events had lesions ranging in size from less than 5 mm to 11 mm in diameter, and a pedicle was present in three patients. No other differences were found between these and asymptomatic patients. All these tumors were on the left side of the heart, with 75% on the mitral valve and 25% on the aortic valve. In these cases stroke was considered secondary to tumor embolism.

Of 24 patients with isolated valvular PFE, none had valve dysfunction or other associated cardiac disease, and all had preserved left ventricular systolic function. Standard open-heart surgery under cardiopulmonary bypass was performed in all patients and successful complete surgical resection of PFE was achieved in all cases. In 21 of the 24 patients simple (shave) excision of the tumor was performed, while excision with valve repair was needed in three cases, but no valve replacement. Valve-sparing surgery was thus performed all cases. No other cardiac procedure was performed concomitantly and there were no major postoperative complications. The median postoperative follow-up was 61.4 (range 7-223) months. In self-reported telephone interviews no deaths, tumor recurrence or embolic events were documented.

Grossly, PFEs appeared as a single (multiple in only two cases) small mass (the largest was 22 mm in size, found in the oldest patient), with delicate, smooth, white papillary fronds, giving a sea anemone-like appearance when placed in water or saline or a flower-like appearance in situ (Figure 2). Microscopically, the papillary fronds were narrow, slender and branching. These fronds, often prominent, surround a layer of myxoid matrix rich in acid mucopolysaccharide and an inner avascular, paucicellular connective core. The peripheral rim and the core contained coarse and fragmented elastic fibers (Figure 3).

Figure 2.

Papillary fibroelastoma of the aortic valve. (A and B) Transesophageal echocardiographic view; (C) photograph of the lesion in situ in the operating room; (D) tumor 1.0 mm×0.8 mm×0.5 mm with characteristic flower-like appearance.

Figure 3.

Microscopic appearance of papillary fibroelastoma. (A) Panoramic view of the lesion showing avascular branching fronds lined by endothelial cells (hematoxylin/eosin stain, original magnification ×16); (B) the fronds consist of a fibrous core surrounded by loose connective tissue and an endothelial lining (hematoxylin/eosin stain, original magnification ×100).


Given the low incidence of these tumors and the lack of longitudinal follow-up studies, their natural history remains poorly understood.

Historically, PFE was first described as a “valvular tumor” in 1931 by Yater,10 and the term “papillary fibroelastoma” was introduced in 1975 by Cheitlin et al.11 In the past, most knowledge of cardiac tumors was based on postmortem studies, but nowadays, with modern echocardiography, such tumors are increasingly diagnosed in vivo. In recent years, several articles have been published providing more information on PFE.2,12,13

Macroscopically, PFE are characterized by multiple frond-like fibrous projections creating a sea anemone-like appearance when immersed in saline. Histologically, the tumor consists of an avascular fibroelastic core, made up of a hyalinized collagen matrix with a rim of smooth muscle cells and elastic fibers, lined by endocardial endothelium.14,15 Although its etiology remains largely unknown, several hypotheses have been reported, including fibroblast infiltration with organization of mural thrombi, virally induced tumor growth and an endocardial response to mechanical trauma or radiation damage.16–18

PFEs most often arise from the valvular endocardium. Gowda et al. found PFEs on valvular surfaces in 84% of cases, although they can also appear on the papillary muscles, chordae tendineae, ventricular septum or endocardial surface.2 Although the tumor can be found anywhere within the heart, in our series it was found primarily on cardiac valves, mitral more often than aortic, unlike other studies in which the aortic valve is the most frequent valve location.2,12,13 Most tumors were solitary, less than 10 mm in diameter, and found in older patients. Multiple lesions are uncommon; they may appear in the same location or in different sites (one patient in our series had two tumors on the aortic valve, and the other had one on the aortic valve and one on the left ventricle). A case report documented up to 40 PFE in both ventricles in one patient.19 In our review, echocardiographic features that suggest PFE with a high degree of suspicion are small size (usually <1.5 cm), attachment by a pedicle or stalk to the endocardium, and some degree of mobility. These characteristics are in agreement with published descriptions.8,9

PFE can be incidental discoveries on echocardiograms, computed tomography scans or magnetic resonance imaging. When symptomatic, they can present in a variety of ways, most commonly with cardiovascular symptoms. Most of our patients (65.4%) were asymptomatic; symptomatic cases (30.8%) were most often due to a thromboembolic cerebrovascular accident. Other documented embolic complications include retinal artery occlusion, myocardial infarction, ischemic extremity, and mesenteric ischemia. Others report symptoms resulting from partial or complete obstruction of valves, ventricular outflow tract, or blood vessels, leading to pulmonary edema, myocardial infarction, heart failure, syncope, or sudden death. PFE has also been associated with conduction abnormalities.20

The management of PFE is the subject of debate but mainly depends on its clinical presentation. Surgical excision is recommended in symptomatic patients, regardless of tumor size. Excision is also recommended in patients undergoing cardiac surgery for other reasons. There is still no consensus on the management of asymptomatic patients. Mariscalco et al.21 proposed a management algorithm, selecting characteristics of the lesion other than location as the determinant for intervention. They suggest that mobile lesions, regardless of size, should be surgically excised given the higher risk of thromboembolic complications. Nonmobile lesions less than 1 cm in diameter can be managed expectantly or with anticoagulation. Although thrombi have been reported on the surface of fibroelastomas, there are no guidelines for evaluating the efficacy of anticoagulation or antiplatelet therapy in affected patients. Gowda et al. identified 25 patients with presumed PFE who did not undergo surgery and were managed with anticoagulation alone, and who had a poor outcome.2 Although asymptomatic PFE can be managed with close echocardiographic follow-up, we believe that surgical excision is more often prudent given the severity of potential embolization, particularly with left-sided PFE. In addition, recurrence of PFE is very low.12

Although the rarity of this cardiac tumor means there are limited data available, the present study, to our knowledge, includes the largest series of patients with PFE in Portugal.

Study limitations

This study is retrospective and relies on the database of a single institution to identify patients. Because it is a small series the association with clinical events is based on indirect evidence.


PFE are uncommon tumors of the endocardium, primarily valvular. They are generally small and single but may be multiple and occur on any endocardial surface. Although mostly asymptomatic they can be associated with embolic events, and may cause other cardiovascular symptoms. Their characteristic echocardiographic appearance means they can readily be recognized. Successful surgical resection of valve tumors can be performed and the native valve can frequently be preserved. Management remains difficult because of the rarity of the tumor. Clinical decisions should be individualized and further studies with longer follow-up are needed. Although the optimal surgical approach remains the subject of debate, in light of our center's experience, surgical removal of the tumor by standard median sternotomy is a safe procedure and has excellent medium- and long-term results.

Funding sources

There were no funding sources for this project.

Conflicts of interest

The authors have no conflicts of interest to declare.


We thank the staff of the Department of Anatomical Pathology of our hospital for their assistance in providing us with the histological images.

B.A. Bruckner, M.J. Reardon.
Benign cardiac tumors: a review.
Methodist DeBakey Cardiovasc J, 6 (2010), pp. 20-26
R.M. Gowda, I.A. Khan, C.K. Nair, et al.
Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases.
Am Heart J, 146 (2003), pp. 404-410
A. Alawi, E.B. Kassabian, R. Ashoush, et al.
Aortic valve papillary fibroelastoma.
Cardiovasc Surg, 10 (2002), pp. 65-67
A. Alozie, F. Prall, C. Hendrikson, et al.
Embolization of multiple papillary fibroelastoma of the aortic valve as cause of a ST-segment elevation myocardial infarction.
Eur J Echocardiogr, 12 (2011), pp. 817
P. Gilbert, C. Bourgault, C. Couture, et al.
Splenic infarction associated with a mobile aortic valve lesion: a case report and review of the literature.
Can J Cardiol, 25 (2009), pp. e215-e216
C.M. Steger, T. Hager, E. Ruttmann.
Primary cardiac tumors: a single-center 41-year experience.
ISRN Cardiol, 2012 (2012), pp. 906109
S.S. Tamin, J.J. Maleszewski, C.G. Scott, et al.
Prognostic and bioepidemiologic implications of papillary fibroelastomas.
JACC, 65 (2015), pp. 2420-2429
K.W. Klarich, M. Enriquez-Sarano, G.M. Gura, et al.
Papillary fibroelastoma: echocardiographic characteristics for diagnosis and pathologic correlation.
J Am Coll Cardiol, 30 (1997), pp. 784-790
G.K. Lund, S. Schroder, D.H. Koschyk, et al.
Echocardiographic diagnosis of papillary fibroelastoma of the mitral and tricuspid valve apparatus.
Clin Cardiol, 20 (1997), pp. 175-177
W.M. Yater.
Tumors of the heart and pericardium: pathology, symptomatology and report of nine cases.
Arch Intern Med, 48 (1931), pp. 627-666
M.D. Cheitlin, H.A. McAllister, C.M. de Castro.
Myocardial infarction without atherosclerosis.
JAMA, 231 (1975), pp. 951-959
J.P. Sun, C.R. Asher, X.S. Yang, et al.
Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients.
Circulation, 103 (2001), pp. 2687-2693
M.M. Anastacio, M.R. Moon, R. Damiano Jr., et al.
Surgical experience with cardiac papillary fibroelastoma over a 15-year period.
Ann Thorac Surg, 94 (2012), pp. 537-541
R.N. de Visser, C. van Mieghem, N.C. van Pelt, et al.
Papillary fibroelastoma of the aortic valve and coronary artery disease visualized by 64-slice CT.
Nat Clin Pract Cardiovasc Med, 5 (2008), pp. 350-353
D. Grandmougin, G. Fayad, D. Moukassa, et al.
Cardiac valve papillary fibroelastomas: clinical, histological and immunohistochemical studies and a physiopathogenic hypothesis.
J Heart Valve Dis, 9 (2000), pp. 832-841
W.R. Salyer, D.L. Page, G.M. Hutchins.
The development of cardiac myxomas and papillary endocardial lesions from mural thrombus.
Am Heart J, 89 (1975), pp. 4-17
A.N. Kurup, H.D. Tazelaar, W.D. Edwards, et al.
Iatrogenic cardiac papillary fibroelastoma: a study of 12 cases (1990 to 2000).
Hum Pathol, 33 (2002), pp. 1165-1169
D.M. Shahian, S.B. Labib, G. Chang.
Cardiac papillary fibroelastoma.
Ann Thorac Surg, 59 (1995), pp. 538-541
T.K. Kumar, K. Kuehl, C. Reyes, et al.
Multiple papillary fibroelastomas of the heart.
Ann Thorac Surg, 88 (2009), pp. e66-e67
H.C. Yee, J.E. Nwosu, A.D. Lii, et al.
Echocardiographic features of papillary fibroelastoma and their consequences and management.
Am J Cardiol, 80 (1997), pp. 811-814
G. Mariscalco, V.D. Bruno, P. Borsani, et al.
Papillary fibroelastoma: insight to a primary cardiac valve tumor.
J Card Surg, 25 (2010), pp. 198-205
Copyright © 2018. Sociedade Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia (English edition)

Subscribe to our newsletter

Article options
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.